Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Novo Nordisk
Femme et Homme Max 99 ans
Novo Nordisk Farma Oy
MAJ Il y a 4 ans
A one-year, multi-national, open-labelled, parallel-group, 2:1 randomised treat-to-target trial comparing efficacy and safety of insulin detemir with insulin glargine using a basal-bolus regimen with insulin aspart as mealtime insulin in subjects with type 1 diabetes
To compare the glycaemic control of insulin detemir with that of insulin glargine as measured by HbA1c in subjects with type 1 diabetes on a basal-bolus regimen with insulin aspart as bolus insulin af...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
Safety and Efficacy of turoctocog alfa pegol (N8-GP) in Previously Untreated Patients with Haemophilia A Evaluar la inmunogenia inmunogenicidad de N8-GP (turoctocog alfa pegol) en pacientes no tratados previamente con hemofilia A grave
To evaluate immunogenicity of N8-GP (turoctocog alfa pegol) in previously untreated patients (PUPs) with severe haemophilia A Evaluar la inmunogeneicidad de N8-GP (turoctocog alfa pegol) en paci...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
A clinical trial comparing efficacy and safety of insulin degludec/liraglutide (IDegLira) in subjects with type 2 diabetes mellitus using two different titration algorithms
To confirm the efficacy of insulin degludec/liraglutide (IDegLira), using a once weekly titration algorithm, in controlling glycaemia in insulin-naïve subjects with type 2 diabetes mellitus (T2DM), in...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
An extension trial to NN1250-3582 comparing safety and efficacy of NN1250 and insulin glargine, both with insulin aspart as meal-time insulin ± OADs in type 2 diabetes A 26 week controlled, open label, multicentre, multinational, treat-to-target extension trial comparing safety and efficacy of SIBA and insulin glargine both administered once daily in a basal-bolus regimen with insulin aspart as mealtime insulin ± treatment with metformin, ± pioglitazone in subjects with type 2 diabetes after a preceding 52 week treatment period with SIBA or insulin glargine both with mealtime insulin aspart ± treatment with metformin, ± pioglitazone in trial NN1250-3582
The primary objective of this extension trial is to investigate the long-term safety and tolerability of NN1250 in combination with insulin aspart. This is done by comparing NN1250 + insulin aspart ± ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
Ensayo para comparar la eficacia y la seguridad de insulina degludec una vez al día en pacientes con diabetes mellitus tipo 2 no tratados previamente con insulina cuando se utilizan dos algoritmos de ajuste de dosis diferentes. "A trial comparing the efficacy and safety of insulin degludec once daily in insulin naïve subjects with type 2 diabetes mellitus when titrated using two different titration algorithms
Confirmar la eficacia del algoritmo sencillo de ajuste de la dosis de insulina degludec 100 U/ml (IDeg) una vez al día (OD) + metformina para controlar la glucemia en cuanto a la variación de la hemog...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
BEGIN™: EASY AM A trial comparing efficacy and safety of NN1250 and insulin glargine in subjects with type 2 diabetes
To confirm the efficacy of SIBA 200 U/mL three times weekly + metformin ± DPP-4 inhibitor in controlling glycaemia with respect to change from baseline in HbA1c after 26 weeks of treatment. This is do...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
A trial investigating single dose pharmacokinetics and safety of turoctocog alfa pegol from two different production processes in patients with severe haemophilia A Ensayo clínico que investiga la farmacocinética y seguridad de una dosis única de turoctocog alfa pegol procedente de dos procesos de producción distintos en pacientes con hemofilia A grave
To evaluate and compare the single-dose pharmacokinetic of turoctocog alfa pegol from the pivotal process with turoctocog alfa pegol from the commercial process, each given as intravenous administrati...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
Efficacy and safety of liraglutide in subjects with type 1 diabetes undergoing islet cell
The primary objective is to investigate if treatment with liraglutide can increase the proportion of subjects who are insulin-independent one year after islet cell transplantation, and required only o...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients with Haemophilia A
• To evaluate safety of N8 in paediatric previously treated patients (PTPs) <12 years of age with haemophilia A
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
A trial investigating the efficacy and safety of insulin degludec in children and adolescents with type 1 diabetes mellitus
To confirm the efficacy of insulin degludec administered once daily plus mealtime insulin aspart in controlling glycaemia with respect to change from baseline in HBA1c after 26 weeks of treatment. Thi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant